Literature DB >> 11283042

Serum immunoglobulin G immune response to Helicobacter pylori antigens in Mongolian gerbils.

T Kumagai1, J Yan, D Y Graham, M Tozuka, Y Okimura, T Ikeno, A Sugiyama, T Katsuyama, H Ota.   

Abstract

The Mongolian gerbil model for Helicobacter pylori infection is an animal model that mimics human disease. We examined the serum immune response to H. pylori infection in gerbils by enzyme-linked immunosorbent assay (ELISA) and Western blotting, both with whole-cell (H. pylori) extracts. A total of 66 7-week-old specific-pathogen-free male gerbils were inoculated orogastrically with H. pylori strain ATCC 43504. Sera were collected 1, 2, 4, 8, 12, 26, 38, and 52 weeks after H. pylori inoculation. Sixty-nine noninfected gerbils and their sera were used as controls. The specificity of the ELISA was 95.7%. The frequency of seropositivity increased over time: 2 of 10 (20%), 7 of 10 (70%), and 7 of 7 (100%) samples of sera from inoculated gerbils were positive for H. pylori at 2, 4, and 8 weeks postinoculation, respectively. Western blot assays showed that the primary immunoglobulin G (IgG) response against low-molecular-mass (25-, 30-, and 20-kDa) proteins appeared after a lag period of 2 to 8 weeks after inoculation. Antibodies against 160-, 150-, 110-, 120-, 80-, 66-, and 63-kDa proteins were observed 12 weeks after inoculation. The early reactive 30-kDa protein was identified as a urease alpha subunit by N-terminal amino acid sequencing. After 26 weeks, two groups of animals could be distinguished: one group developed ulcers (n = 5), and the other developed hyperplastic polyps without ulcers (n = 19). Gerbils in the gastric ulcer group showed significantly higher serum anti-H. pylori IgG levels than did gerbils in the hyperplastic group (P = 0.001) as measured by ELISA. Furthermore, a higher proportion of animals developed antibodies to H. pylori proteins of 26, 25, and 20 kDa in the ulcer group than those animals with hyperplastic polyps (75 to 100% versus 17 to 50%) in Western blot assays. These results highlight the importance of the immune response of the host in the development of H. pylori-related gastric lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283042      PMCID: PMC87925          DOI: 10.1128/JCM.39.4.1283-1288.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Induction of gastric ulcer and intestinal metaplasia in mongolian gerbils infected with Helicobacter pylori.

Authors:  F Hirayama; S Takagi; H Kusuhara; E Iwao; Y Yokoyama; Y Ikeda
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Quantification of total IgM and IgG and specific IgM and IgG to a thymus-independent (LPS) and a thymus-dependent (tetanus toxoid) antigen in the rat by enzyme-linked immunosorbent assay (ELISA).

Authors:  J G Vos; J Buys; P Beekhof; A M Hagenaars
Journal:  Ann N Y Acad Sci       Date:  1979-05-31       Impact factor: 5.691

4.  Helicobacter pylori infection induces gastric cancer in mongolian gerbils.

Authors:  T Watanabe; M Tada; H Nagai; S Sasaki; M Nakao
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

5.  Characterization of an immunoreactive species-specific 19-kilodalton outer membrane protein from Helicobacter pylori by using a monoclonal antibody.

Authors:  E B Drouet; G A Denoyel; M Boude; E Wallano; M Andujar; H P de Montclos
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

6.  Two-dimensional gel electrophoresis and immunoblotting of Campylobacter pylori proteins.

Authors:  B E Dunn; G I Perez-Perez; M J Blaser
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

7.  Isolation and biochemical and molecular analyses of a species-specific protein antigen from the gastric pathogen Helicobacter pylori.

Authors:  P W O'Toole; S M Logan; M Kostrzynska; T Wadström; T J Trust
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

8.  Ultrastructural localization of urease of Helicobacter pylori.

Authors:  G Bode; P Malfertheiner; G Lehnhardt; M Nilius; H Ditschuneit
Journal:  Med Microbiol Immunol       Date:  1993-11       Impact factor: 3.402

9.  Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country.

Authors:  H M Mitchell; S L Hazell; Y Y Li; P J Hu
Journal:  Am J Gastroenterol       Date:  1996-09       Impact factor: 10.864

10.  Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.

Authors:  J L Telford; P Ghiara; M Dell'Orco; M Comanducci; D Burroni; M Bugnoli; M F Tecce; S Censini; A Covacci; Z Xiang
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  13 in total

1.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; Yoshio Yamaoka
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

3.  Helicobacter pylori outer membrane proteins on gastric mucosal interleukin 6 and 11 expression in Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; David Y Graham; Yoshio Yamaoka
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

4.  Roles of virD4 and cagG genes in the cag pathogenicity island of Helicobacter pylori using a Mongolian gerbil model.

Authors:  H Saito; Y Yamaoka; S Ishizone; F Maruta; A Sugiyama; D Y Graham; K Yamauchi; H Ota; S Miyagawa
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans.

Authors:  Zhannat Z Nurgalieva; Margaret E Conner; Antone R Opekun; Carl Q Zheng; Susan N Elliott; Peter B Ernst; Michael Osato; Mary K Estes; David Y Graham
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Natural history of gastric mucosal cytokine expression in Helicobacter pylori gastritis in Mongolian gerbils.

Authors:  Yoshio Yamaoka; Kazuyoshi Yamauchi; Hiroyoshi Ota; Atsushi Sugiyama; Satoshi Ishizone; David Y Graham; Fukuto Maruta; Maki Murakami; Tsutomu Katsuyama
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

7.  Development of an animal model of Helicobacter pylori (Indian strain) infection.

Authors:  Kanchan K Mishra; Shashikant Srivastava; Archana Aayyagari; Kanjaksha Ghosh
Journal:  Indian J Gastroenterol       Date:  2019-03-25

8.  Long-term infection of Mongolian gerbils with Helicobacter pylori: microbiological, histopathological, and serological analyses.

Authors:  Shigehito Nakagawa; Takako Osaki; Yasunori Fujioka; Hiroyuki Yamaguchi; Shigeru Kamiya
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

9.  Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; David Y Graham; Yoshio Yamaoka
Journal:  Cancer Sci       Date:  2009-07-21       Impact factor: 6.716

10.  Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Authors:  Patricia Londoño-Arcila; Donna Freeman; Harry Kleanthous; Aisling M O'Dowd; Susan Lewis; Arthur K Turner; Emma L Rees; Timothy J Tibbitts; Judith Greenwood; Thomas P Monath; Michael J Darsley
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.